Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
By P. Philip, J. Benedetti, Christopher Corless, R. Wong, E. O’Reilly, P. Flynn, K. Rowland, J. Atkins, B. Mirtsching, S. Rivkin and 5 more. Journal of Clinical Oncology, 2010
604 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/0a19afde0c108cd55377e5ef7ff13bc29ef41691
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Recent progress in pancreatic cancer (2013, background): “The addition of cetuximab to gemcitabine, and of bevacizumab (vascular endothelial growth factor [VEGF] inhibitor) to gemcitabine both demonstrated no survival benefit and an increase in toxicities in phase 2 and 3 trials.(166,201) The newest combination regimen for patients with metastatic pancreat”